About US
Contact us
-
Lilly freezes salaries ahead of patent loss for CymbaltaEli Lilly's ($LLY) CEOJohn Lechleiterwas out for a couple of months as he dealt with some heart issues. He recently returned, and guess what he brought with him? More bad news for employees. The Indi2013/7/18
-
CFDA releases the first issue of 2013 National Medical Device Quality AnnouncementChina Food and Drug Administration (CFDA) recently released the first issue of 2013 National Medical Device Quality Announcement and publicized the quality sampling and testing results of balloon dila2013/7/16
-
China calls GSK 'godfather' in alleged bribery schemeProbe turns up information other drugmakers doing the same Western drugmakers holding their breath, worried that they may be the next target for bribery inChina, can't yet come up for air. Chinese la2013/7/16
-
Roche may want Alexion, but is the price right?Roche may have the wherewithal to bid for Alexion and an appetite for the company's rare-disease drugs. But it might not have the stomach for the price. Roche ($RHHBY) is reportedly scouting for fina2013/7/16
-
Novartis CEO Jimenez says China is a difficult market, but worth itChinais a huge market and offers huge potential for pharma. But it is an increasingly challenging place to do business for Western drugmakers, as GlaxoSmithKline's ($GSK) run-in with authorities over2013/7/15
-
Telegraph: Sources say 30 GSK employees under house arrestChina-watchers think probes part of effort to divert attention away from domestic shortcomings Reports are starting to put a few details around what is going on with more than two dozen GlaxoSmithKli2013/7/15
-
Chinese authorities say GSK employees confess to briberyLast month GSK fired R&D chief in China for alleged misconduct GlaxoSmithKline ($GSK) has for weeks been saying that it could find no evidence to confirm allegations that any of its employees inC2013/7/12
-
BMS, Pfizer say FDA to review Eliquis for new useThe FDA will considerEliquisfor a new indication, one which Pfizer ($PFE) and partner Bristol-Myers Squibb ($BMY) hope can help the blood thinner hit the sales potential analysts predicted for the dru2013/7/12
-
Pharma, FDA still lagging in post-marketing safety researchThe good news: Drugmakers are wrapping up more post-marketing safety studies, now that the FDA can crack the whip. More good news: Companies got to work on a bigger proportion of the studies required.2013/7/11
-
Risperdal plaintiff's lawyer demands sealed J&J docs from FDAIf you don't succeed in court, try the FDA. That's the approach of a Philadelphia lawyer who wants to make someRisperdaldata public, but is barred from doing so by a federal judge's order. As thePhil2013/7/11